anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 236,071-236,100
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

236,071-236,100 of 303,780

filter-aware
07
The chart uses a red vertical arrow to quantify the 132-point gap between the market and Pfizer.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
08
The chart uses a custom bridge structure to calculate total value lost by adding market cap decline and COVID benefit.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
09
The chart highlights LLY and NVO as GLP-1 participants; PFE is highlighted in a different color.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
11
Starboard Value | Activist Presentation Deck | 74 slidesStarboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)1 hit
15
The slide uses a quote to highlight a specific management commitment, likely to be contrasted with later performance.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)Loop · Iceberg1 hit
16
The slide is used by Starboard Value to contrast Pfizer's historical R&D projections with current performance.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)Loop · Iceberg1 hit
17
The slide uses a table to track 15 specific drug programs, noting their therapeutic area, next steps, and timing, with symbols indicating status (check for approval, star for designation, box for negative data).Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)Loop · Iceberg1 hit
18
The slide uses a table to highlight specific programs that had already achieved approvals or failed (negative pivotal data) to challenge the company's narrative.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)Loop · Iceberg1 hit
21
Uses a screenshot of a news article as evidence of failure.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)1 hit
22
Uses a red arrow annotation to emphasize the gap between projected 2030 sales and the blockbuster threshold.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)1 hit
23
The slide uses a visual gap analysis to highlight the shortfall against a market benchmark.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)1 hit
24
The slide uses a highlighted excerpt from a third-party report to undermine the company's R&D track record.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)1 hit
27
The slide uses a direct quote from a press release to highlight a clinical trial failure.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)1 hit
28
The slide uses a primary source excerpt to establish the clinical efficacy and subsequent commercial success of the drug.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)1 hit
29
The slide uses a screenshot of a news article as evidence.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)1 hit
30
The slide highlights a contradiction between the CEO's stated focus on innovation and the market's focus on shareholder return.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Beat · Agitate (Make it worse)1 hit
32
Uses highlighted text to draw attention to specific claims within the quotes.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
33
The slide highlights the skepticism of Wall Street analysts regarding management's projections.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
34
Uses a 'villain critique' style to undermine management's R&D track record.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
35
The chart highlights the massive gap between company optimism and market reality.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
37
Starboard Value | Activist Presentation Deck | 74 slidesStarboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
38
The chart highlights Pfizer's underperformance relative to peers, including a specific callout for 'PFE Excl. COVID'.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
39
The chart uses a 'broken axis' visual style for the top two bars (LLY, NVO) to accommodate their significantly higher growth rates.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
40
The chart uses a broken axis for the top two performers (NVO, LLY) to accommodate the scale.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
41
Starboard Value | Activist Presentation Deck | 74 slidesStarboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor 1 hit
42
The slide highlights the scale of capital allocation into M&A, framing it as a potential misuse of COVID-19 windfall cash.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Loop · Cost Of Inaction1 hit
43
The slide uses a visual comparison to contrast the $70B spend against the $20.5B revenue target, implying poor capital allocation.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Loop · Cost Of Inaction1 hit
44
The chart uses a red bar to emphasize the outlier status of the 'PFE Consolidated Deals (Mgmt)' metric.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Loop · Cost Of Inaction1 hit
45
The slide uses a stacked bar chart to contrast company expectations ($20.5bn) against sell-side consensus ($13.3bn).Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Loop · Cost Of Inaction1 hit
46
The chart highlights the discrepancy between management's valuation assumptions and consensus expectations.Starboard Value | Activist Presentation Deck | 74 slides · Starboard Value
Activist deck Activist investor Loop · Cost Of Inaction1 hit